Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease

Neuroscience Letters

Volumn 460, Issue 2, 2009, Pages 180-184

  Dwyer, Barney E ^a,b   Smith, Mark A ^c   Richardson, Sandy L ^c   Perry, George ^c,d   Zhu, Xiongwei ^c  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d University of San Antonio   (United States)

Author keywords

Alzheimer's disease; Heme; Neurodegenerative disease

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; APOLIPOPROTEIN E; HEME; HEME OXYGENASE; PORPHOBILINOGEN DEAMINASE; PORPHOBILINOGEN SYNTHASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; ENZYME REGULATION; FEMALE; GENE EXPRESSION; GENOTYPE; HEME SYNTHESIS; HUMAN; HUMAN TISSUE; HYPOTHESIS; IRON METABOLISM; MALE; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

5-AMINOLEVULINATE SYNTHETASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYMETHYLBILANE SYNTHASE; MALE; PORPHOBILINOGEN SYNTHASE; RNA, MESSENGER;

EID: 67349213608     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.05.058     Document Type: Article

References (49)

1. Ajioka R.S., Phillips J.D., and Kushner J.P. Biosynthesis of heme in mammals. Biochim. Biophys. Acta 1763 (2006) 723-736
2. Albers J.W., and Fink J.K. Porphyric neuropathy. Muscle Nerve 30 (2004) 410-422
3. Atamna H., and Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 3381-3386
4. Atamna H., and Frey II W.H. A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11153-11158
5. Chernova T., Nicotera P., and Smith A.G. Heme deficiency is associated with senescence and causes suppression of N-methyl-d-aspartate receptor subunits expression in primary cortical neurons. Mol. Pharmacol. 69 (2006) 697-705
6. de Kok J.B., Roelofs R.W., Giesendorf B.A., Pennings J.L., Waas E.T., Feuth T., Swinkels D.W., and Span P.N. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab. Invest. 85 (2005) 154-159
7. de la Monte S.M., and Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 7 (2005) 45-61
8. Devi L., Prabhu B.M., Galati D.F., Avadhani N.G., and Anandatheerthavarada H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26 (2006) 9057-9068
9. Fukuda H., Casas A., and Batlle A. Aminolevulinic acid: from its unique biological function to its star role in photodynamic therapy. Int. J. Biochem. Cell Biol. 37 (2005) 272-276
10. Gatta L.B., Vitali M., Verardi R., Arosio P., and Finazzi D. Inhibition of heme synthesis alters amyloid precursor protein processing. J. Neural Transm. 116 (2009) 79-88
11. Greenbaum L., Gozlan Y., Schwartz D., Katcoff D.J., and Malik Z. Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?. Br. J. Cancer 86 (2002) 1006-1011
12. Greenbaum L., Katcoff D.J., Dou H., Gozlan Y., and Malik Z. A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells. Oncogene 22 (2003) 5221-5228
13. Guo G.G., Gu M., and Etlinger J.D. 240-kDa proteasome inhibitor (CF-2) is identical to delta-aminolevulinic acid dehydratase. J. Biol. Chem. 269 (1994) 12399-12402
14. Handschin C., Lin J., Rhee J., Peyer A.K., Chin S., Wu P.H., Meyer U.A., and Spiegelman B.M. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122 (2005) 505-515
15. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., and Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21 (2001) 3017-3023
16. Kimpara T., Takeda A., Yamaguchi T., Arai H., Okita N., Takase S., Sasaki H., and Itoyama Y. Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease. Neurobiol. Aging 21 (2000) 551-554
17. Kolluri S., Sadlon T.J., May B.K., and Bonkovsky H.L. Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem. J. 392 (2005) 173-180
18. Kontush A., Berndt C., Weber W., Akopyan V., Arlt S., Schippling S., and Beisiegel U. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30 (2001) 119-128
19. Lee H.G., Zhu X., Nunomura A., Perry G., and Smith M.A. Amyloid beta: the alternate hypothesis. Curr. Alzheimer Res. 3 (2006) 75-80
20. Maines M.D. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2 (1988) 2557-2568
21. Meissner P.N., Hift R.J., and Kirsch R.E. The porphyrias. In: Arias I.M., Boyer J.L., Chisari F.V., Fausto N., Schacter D., and Shafritz D.A. (Eds). The Liver: Biology and Pathobiology (2001), Lippincott, Williams and Wilkins, Philadelphia 311-329
22. Moraes C.T., Diaz F., and Barrientos A. Defects in the biosynthesis of mitochondrial heme c and heme a in yeast and mammals. Biochim. Biophys. Acta 1659 (2004) 153-159
23. Munakata H., Sun J.Y., Yoshida K., Nakatani T., Honda E., Hayakawa S., Furuyama K., and Hayashi N. Role of the heme regulatory motif in the heme-mediated inhibition of mitochondrial import of 5-aminolevulinate synthase. J. Biochem. 136 (2004) 233-238
24. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
25. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., and Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19 (1999) 1959-1964
26. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med. 12 (2008) 363-373
27. Perry G., Nunomura A., Hirai K., Takeda A., Aliev G., and Smith M.A. Oxidative damage in Alzheimer's disease: the metabolic dimension. Int. J. Dev. Neurosci. 18 (2000) 417-421
28. Perry G., Nunomura A., Raina A.K., Aliev G., Siedlak S.L., Harris P.L., Casadesus G., Petersen R.B., Bligh-Glover W., Balraj E., Petot G.J., and Smith M.A. A metabolic basis for Alzheimer disease. Neurochem. Res. 28 (2003) 1549-1552
29. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A.L., Zhu X., Raina A.K., Holbrook N., Siedlak S.L., Harris P.L., and Smith M.A. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10 (1999) 2411-2415
30. Premkumar D.R., Smith M.A., Richey P.L., Petersen R.B., Castellani R., Kutty R.K., Wiggert B., Perry G., and Kalaria R.N. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J. Neurochem. 65 (1995) 1399-1402
31. Roberts A.G., and Elder G.H. Alternative splicing and tissue-specific transcription of human and rodent ubiquitous 5-aminolevulinate synthase (ALAS1) genes. Biochim. Biophys. Acta 1518 (2001) 95-105
32. Roberts A.G., Redding S.J., and Llewellyn D.H. An alternatively-spliced exon in the 5′-UTR of human ALAS1 mRNA inhibits translation and renders it resistant to haem-mediated decay. FEBS Lett. 579 (2005) 1061-1066
33. Rottkamp C.A., Raina A.K., Zhu X., Gaier E., Bush A.I., Atwood C.S., Chevion M., Perry G., and Smith M.A. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 30 (2001) 447-450
34. Santpere G., Nieto M., Puig B., and Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neurosci. Lett. 397 (2006) 30-34
35. Schipper H.M., Bennett D.A., Liberman A., Bienias J.L., Schneider J.A., Kelly J., and Arvanitakis Z. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol. Aging 27 (2006) 252-261
36. Schipper H.M., Cisse S., and Stopa E.G. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann. Neurol. 37 (1995) 758-768
37. Sengupta A., Hon T., and Zhang L. Heme deficiency suppresses the expression of key neuronal genes and causes neuronal cell death. Brain Res. Mol. Brain Res. 137 (2005) 23-30
38. Smith M.A., Casadesus G., Joseph J.A., and Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33 (2002) 1194-1199
39. Smith M.A., Harris P.L., Sayre L.M., and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 9866-9868
40. Smith M.A., Kutty R.K., Richey P.L., Yan S.D., Stern D., Chader G.J., Wiggert B., Petersen R.B., and Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145 (1994) 42-47
41. Takahashi T., Shimizu H., Morimatsu H., Inoue K., Akagi R., Morita K., and Sassa S. Heme oxygenase-1: a fundamental guardian against oxidative tissue injuries in acute inflammation. Mini Rev. Med. Chem. 7 (2007) 745-753
42. Thakur A., Wang X., Siedlak S.L., Perry G., Smith M.A., and Zhu X. c-Jun phosphorylation in Alzheimer disease. J. Neurosci. Res. 85 (2007) 1668-1673
43. Tsiftsoglou A.S., Tsamadou A.I., and Papadopoulou L.C. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol. Ther. 111 (2006) 327-345
44. Wang X., Su B., Perry G., Smith M.A., and Zhu X. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic. Biol. Med. 43 (2007) 1569-1573
45. Webber K.M., Smith M.A., Lee H.G., Harris P.L., Moreira P., Perry G., and Zhu X. Mitogen- and stress-activated protein kinase 1: convergence of the ERK and p38 pathways in Alzheimer's disease. J. Neurosci. Res. 79 (2005) 554-560
46. Yoo H.W., Warner C.A., Chen C.H., and Desnick R.J. Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene. Genomics 15 (1993) 21-29
47. Zhu X., Lee H.G., Perry G., and Smith M.A. Alzheimer disease, the two-hit hypothesis: an update. Biochim. Biophys. Acta 1772 (2007) 494-502
48. Zhu X., Ogawa O., Wang Y., Perry G., and Smith M.A. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J. Neurochem. 85 (2003) 87-93
49. Zhu X., Raina A.K., Perry G., and Smith M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3 (2004) 219-226